Valuation: Finch Therapeutics Group, Inc.

Market Cap 18.15M 15.87M 14.64M 13.52M 25.66M 1.73B 26.09M 175M 68.69M 853M 68.13M 66.65M 2.93B P/E 2022
-0.2x
P/E 2023 -0.08x
Enterprise Value 23.15M 20.25M 18.68M 17.25M 32.73M 2.21B 33.28M 223M 87.63M 1.09B 86.91M 85.02M 3.74B EV / Sales 2022
5.01x
EV / Sales 2023 101x
Free-Float
100%
Yield 2022 *
-
Yield 2023 -
1 day+0.29%
1 week+0.48%
Current month+4.46%
1 month+40.67%
3 months+31.88%
6 months-24.64%
Current year-21.78%
1 week 10.52
Extreme 10.52
10.55
1 month 7.25
Extreme 7.25
10.55
Current year 2
Extreme 2
14.4
1 year 2
Extreme 2
16.1
3 years 0.8
Extreme 0.8
16.1
5 years 0.8
Extreme 0.8
521.7
10 years 0.8
Extreme 0.8
675
Manager TitleAgeSince
Chief Executive Officer - 16/05/2023
Director of Finance/CFO 60 16/05/2023
Director TitleAgeSince
Director/Board Member 71 01/09/2017
Chairman 60 -
Director/Board Member 60 25/09/2019
Date Insider Type Main position Quantity % Market Cap.
07/06/24Don

Director

767 0.0478%
20/05/24Don

Director

3,750 0.2335%
28/03/24Sell

Director

8,242 0.5133%
Change 5-day change 1-year change 3-year change Capi.($)
+0.29%+0.48%-17.25%+18.27% 16.94M
-0.41%+0.62%+3.44%+9.94% 50.73B
-2.22%-1.25%+391.53%+593.69% 39.73B
-0.54%+0.39%+27.67%-5.10% 34.69B
-1.36%+0.35%+19.34%+55.53% 33.21B
+1.21%-4.58%+3.00%+31.73% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+66.38%+122.57% 15.37B
-0.32%+0.23%+14.46%+16.24% 13.78B
-0.62%-3.09%+11.43%-31.02% 12.85B
Average -0.44%-0.70%+57.78%+90.21% 24.39B
Weighted average by Cap. -0.59%-0.23%+82.68%+124.68%

Financials

2022 2023
Net sales 861K 753K 695K 642K 1.22M 82.12M 1.24M 8.3M 3.26M 40.45M 3.23M 3.16M 139M 107K 93.59K 86.33K 79.73K 151K 10.21M 154K 1.03M 405K 5.03M 402K 393K 17.28M
Net income -115M -100M -92.5M -85.43M -162M -10.93B -165M -1.11B -434M -5.39B -430M -421M -18.52B -74.75M -65.39M -60.31M -55.7M -106M -7.13B -107M -721M -283M -3.51B -281M -275M -12.07B
Net Debt -18.68M -16.34M -15.07M -13.92M -26.41M -1.78B -26.86M -180M -70.72M -878M -70.14M -68.61M -3.02B 5M 4.38M 4.04M 3.73M 7.07M 477M 7.19M 48.22M 18.94M 235M 18.78M 18.37M 808M
Logo Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc. is a microbiome technology company with a portfolio of intellectual property and microbiome assets. It is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. It has an intellectual property estate, including more than 113 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. Its assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.
Employees
1
Date Price Change Volume
09/07/26 USD 10.55 +0.29% 215
  1. Stock Market
  2. Stocks
  3. FNCHQ Stock